{"id":4001,"date":"2019-01-24T11:29:26","date_gmt":"2019-01-24T05:59:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4001"},"modified":"2024-09-18T15:09:31","modified_gmt":"2024-09-18T09:39:31","slug":"the-business-cocktail-53","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53","title":{"rendered":"BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M"},"content":{"rendered":"\n<p class=\"has-text-color has-background has-medium-font-size has-very-light-gray-color has-very-dark-gray-background-color\"><strong>BridgeBio\nbags USD 299 Million for <\/strong><strong>genetic diseases<\/strong><\/p>\n\n\n\n<p><strong>BridgeBio Pharma<\/strong> has&nbsp;received&nbsp;a <strong>USD299.2 million<\/strong> for its progress in <strong>genetic disease pipeline.<\/strong> This includes assets in preclinical and clinical development.&nbsp;Several therapeutic areas are being taken under the consideration of the pharma. Also, they aim at a broad range of indications like <a href=\"https:\/\/www.delveinsight.com\/report-store\/transthyretin-amyloidosis-attr-market-2027\">transthyretin amyloidosis (ATTR),<\/a> <strong>pantothenate kinase-associated neurodegeneration (PKAN), Gorlin syndrome and frequent <a href=\"https:\/\/www.delveinsight.com\/report-store\/basal-cell-carcinoma-basal-cell-epithelioma-market\">basal cell <\/a>carcinomas, Netherton syndrome, molybdenum cofactor deficiency Type A, and FGFR, SHP-2, and K-RAS-driven cancers<\/strong> and others.&nbsp;<\/p>\n\n\n\n<p class=\"has-text-color has-background has-medium-font-size has-very-light-gray-color has-very-dark-gray-background-color\"><strong>Immunochina\nreceives USD 20 Million for blood cancer CAR-T<\/strong><\/p>\n\n\n\n<p>The <strong>Beijing biotech<\/strong>, <strong>Immunochina <\/strong>has raised <strong>USD 20 million<\/strong> in third-round financing to accelerate its CAR-T development programs. The company&nbsp;announced&nbsp;the capital will be used in extending its manufacturing capacity as well as funding trials of its lead CAR-T IM19 for <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-chronic-lymphocytic-leukemia-market\">B-cell acute lymphoblastic <g class=\"gr_ gr_7 gr-alert gr_spell gr_inline_cards gr_disable_anim_appear ContextualSpelling multiReplace\" id=\"7\" data-gr-id=\"7\">leukemia<\/g><\/a> (B-ALL) and <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-nhl-market\">non-Hodgkin\u2019s lymphoma<\/a>. Immunochina is aiming domestic market of China for becoming an international CAR-T player.<\/p>\n\n\n\n<p class=\"has-text-color has-background has-medium-font-size has-very-light-gray-color has-very-dark-gray-background-color\"><strong>Attune\nPharmaceuticals raises USD 23 Million for oral HAE drug<\/strong><\/p>\n\n\n\n<p><strong>Attune Pharmaceuticals<\/strong>&nbsp;receives&nbsp;USD 23 million in series B financing for its oral drug for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\">hereditary angioedema (HAE)<\/a>.<\/strong> The company targets to provide an oral alternative to approved treatments.&nbsp;The&nbsp;financing&nbsp;comes after the company presented phase 1&nbsp;data for ATN-249.&nbsp;In addition to progressing the HAE candidate, <strong>ATN-249<\/strong>, the funding will also bolster the development of Attune\u2019s preclinical pipeline.&nbsp;<\/p>\n\n\n\n<p class=\"has-text-color has-background has-medium-font-size has-very-light-gray-color has-very-dark-gray-background-color\"><strong>Wren\nreceives <\/strong><strong>USD 23 million\nto drug protein-misfolding diseases<\/strong><\/p>\n\n\n\n<p><strong>Wren Therapeutics<\/strong> has&nbsp;raised&nbsp;<strong>USD 23 million<\/strong>. The British biotech will use the capital for the series A round to progress its research into drugs to treat protein-misfolding diseases such as Alzheimer\u2019s. The biotech progresses a technology, which will be potentially applicable to a plethora of diseases that emerge from the misfolding and malfunction of proteins, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson\u2019s <\/a>and Type 2 diabetes. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has&nbsp;received&nbsp;a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development.&nbsp;Several therapeutic areas are being taken under the consideration of the pharma. Also, they aim at a broad range of indications like transthyretin amyloidosis (ATTR), pantothenate kinase-associated neurodegeneration [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4002,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2482,2470,2480,2471,2483,2481,2476,2478,2472,2484],"industry":[17225],"therapeutic_areas":[17240,17233,17245,17228,17234],"class_list":["post-4001","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-attune-pharmaceuticals","tag-bridgebio-pharma","tag-fgfr","tag-genetic-disease-pipeline","tag-hereditary-angioedema-hae","tag-immunochina","tag-netherton-syndrome","tag-shp-2","tag-transthyretin-amyloidosis-attr","tag-wren-therapeutics","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio bags $299M; Immunochina receives $20M; Attune raises<\/title>\n<meta name=\"description\" content=\"BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical develo....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio bags $299M; Immunochina receives $20M; Attune raises\" \/>\n<meta property=\"og:description\" content=\"BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical develo....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-24T05:59:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:39:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1400\" \/>\n\t<meta property=\"og:image:height\" content=\"1050\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BridgeBio bags $299M; Immunochina receives $20M; Attune raises","description":"BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical develo....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53","og_locale":"en_US","og_type":"article","og_title":"BridgeBio bags $299M; Immunochina receives $20M; Attune raises","og_description":"BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical develo....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-24T05:59:26+00:00","article_modified_time":"2024-09-18T09:39:31+00:00","og_image":[{"width":1400,"height":1050,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53","name":"BridgeBio bags $299M; Immunochina receives $20M; Attune raises","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","datePublished":"2019-01-24T05:59:26+00:00","dateModified":"2024-09-18T09:39:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical develo....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-53#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","width":1400,"height":1050,"caption":"merck"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Attune Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BridgeBio Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FGFR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">genetic disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hereditary angioedema (HAE)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immunochina<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Netherton syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SHP-2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Transthyretin Amyloidosis (ATTR)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Wren Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Attune Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">BridgeBio Pharma<\/span>","<span class=\"advgb-post-tax-term\">FGFR<\/span>","<span class=\"advgb-post-tax-term\">genetic disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">hereditary angioedema (HAE)<\/span>","<span class=\"advgb-post-tax-term\">Immunochina<\/span>","<span class=\"advgb-post-tax-term\">Netherton syndrome<\/span>","<span class=\"advgb-post-tax-term\">SHP-2<\/span>","<span class=\"advgb-post-tax-term\">Transthyretin Amyloidosis (ATTR)<\/span>","<span class=\"advgb-post-tax-term\">Wren Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jan 24, 2019","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Jan 24, 2019 11:29 am","modified":"Updated on Sep 18, 2024 3:09 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4001"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4001\/revisions"}],"predecessor-version":[{"id":29621,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4001\/revisions\/29621"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4002"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4001"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4001"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}